Skip to main content
. 2020 Sep 6;2:100021. doi: 10.1016/j.lanwpc.2020.100021

Table 3.

Comorbidities of NMOSD during 2016–2018.

Comorbidities, No. (%) 2016 (n=4580)
2017 (n=5768)
2018 (n=7068)
Child (n=262) Adult (n=4318) Child (n=344) Adult (n=5424) Child (n=413) Adult (n=6655)
Hypertension 4 (1•5) 572 (13•2) 1 (0•3) 750 (13•8) 1 (0•2) 991 (14•9)
Diabetes 1 (0•4) 274 (6•3) 2 (0•6) 374 (6•9) 3 (0•7) 515 (7•7)
Hyperlipidemia 3 (1•1) 551 (12•8) 3 (0•9) 752 (13•9) 4 (1) 891 (13•4)
Osteoporosis 0 (0) 146 (3•4) 0 (0) 204 (3•8) 0 (0) 258 (3•9)
Stroke 1 (0•4) 283 (6•6) 0 (0) 401 (7•4) 1 (0•2) 517 (7•8)
Malignant tumor 0 (0) 37 (0•9) 0 (0) 66 (1•2) 1 (0•2) 79 (1•2)
Depression/anxiety 2 (0•8) 171 (4) 4 (1•2) 220 (4•1) 4 (1) 331 (5)
Autoimmune diseases 15 (5•7) 379 (8•8) 11 (3•2) 586 (10•8) 18 (4•4) 741 (11•1)
Bechet's disease 0 (0) 7 (0•2) 0 (0) 2 (0) 0 (0) 4 (0•1)
Sjögren's syndrome 5 (1•9) 261 (6) 4 (1•2) 372 (6•9) 5 (1•2) 477 (7•2)
SLE 8 (3•1) 78 (1•8) 5 (1•5) 137 (2•5) 11 (2•7) 148 (2•2)
Arthritis 0 (0) 1 (0) 0 (0) 0 (0) 0 (0) 1 (0)
Other 2 (0•8) 32 (0•7) 2 (0•6) 75 (1•4) 2 (0•5) 111 (1•7)

SLE: Systemic lupus erythematosus.